Goldman Sachs announced Impax Laboratories Inc. (NASDAQ:IPXL), bumping up its stock price target to $26.00 earlier today
- Updated: September 26, 2016
Reporting a potential upside of 0.02%, Goldman Sachs upped the price target of Impax Laboratories Inc. (NASDAQ:IPXL) to $26.00
On 8/15/2016, Northland Securities released a statement about Impax Laboratories Inc. (NASDAQ:IPXL) upped the target price from $0.00 to $30.00 that suggested an upside of 0.25%.
Having a price of $25.40, Impax Laboratories Inc. (NASDAQ:IPXL) traded -4.11% lower on the day. With the last stock price down -15.89% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. IPXL has recorded a 50-day average of $24.51 and a two hundred day average of $30.20. Trade Volume was up over the average, with 1,127,188 shares of IPXL changing hands over the typical 949,588
Recent Performance Chart
Impax Laboratories Inc. has PE ratio of 53.81 with a one year low of $20.97 and a one year high of $45.00 and has a market capitalization of $0.
A total of 14 brokerages have issued a ratings update on Impax Laboratories Inc.. Two brokerages rating the company a strong buy, 3 firms rating the stock a buy, 7 firms rating the stock a hold, 3 firms rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $35.79.
Brief Synopsis On Impax Laboratories Inc. (NASDAQ:IPXL)
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.